New Key Publication:Hepatic ChREBP activation limits NAFLD development in a mouse model for Glycogen Storage Disease type Ia
Abstract:
Glycogen storage disease type Ia (GSD Ia) is an inborn error of metabolism caused by defective glucose-6-phosphatase (G6PC) activity. GSD Ia patients exhibit severe hepatomegaly due to glycogen and triglyceride (TG) accumulation in the liver. We have previously shown that the activity of Carbohydrate Response Element Binding Protein (ChREBP), a key regulator of glycolysis and de novo lipogenesis, is increased in GSD Ia. In the current study we assessed the contribution of ChREBP to non-alcoholic fatty liver disease (NAFLD) development in a mouse model for hepatic GSD Ia. Liver-specific G6pc knockout (L-G6pc-/-) mice were treated with AAV2/8-shChREBP to normalize hepatic ChREBP activity to levels observed in wildtype (L-G6pc+/+) mice receiving AAV8-shScramble. Hepatic ChREBP knockdown markedly increased liver weight and hepatocyte size in L-G6pc /- mice. This was associated with hepatic accumulation of G6P, glycogen and lipids, while the expression of glycolytic and lipogenic genes was reduced. Enzyme activities, flux measurements, hepatic metabolite analysis and VLDL-TG secretion assays revealed that hepatic ChREBP knockdown reduced downstream glycolysis and de novo lipogenesis, but also strongly suppressed hepatic VLDL lipidation hence promoting the storage of ‘old fat’. Interestingly, enhanced VLDL-TG secretion in shScramble-treated L-G6pc-/- mice associated with a ChREBP-dependent induction of the VLDL lipidation proteins MTTP and TM6SF2, the latter being confirmed by ChIP-PCR.
Conclusion: Attenuation of hepatic ChREBP induction in GSD Ia liver aggravates hepatomegaly due to further accumulation of glycogen and lipids as a result of reduced glycolysis and suppressed VLDL-TG secretion. TM6SF2, critical for VLDL formation, was identified as a novel ChREBP target in mouse liver. Altogether, our data show that enhanced ChREBP activity limits NAFLD development in GSD Ia by balancing hepatic TG production and -secretion.
by:
- Yu Lei
- Joanne A. Hoogerland
- Vincent W. Bloks
- Trijnie Bos
- Aycha Bleeker
- Henk Wolters
- Justina C. Wolters
- Brenda S. Hijmans
- Theo H. van Dijk
- Rachel Thomas
- Michel van Weeghel
- Gilles Mithieux
- Riekelt H. Houtkooper
- Alain de Bruin
- Fabienne Rajas
- Folkert Kuipers
- Maaike H. Oosterveer
Hepatology: Hepatic ChREBP activation limits NAFLD development in a mouse model for Glycogen Storage Disease type Ia
| Last modified: | 21 February 2020 8.28 p.m. |
More news
-
28 March 2023
A leap of faith: from research to enterprise
Having ideas, experimenting and trying things out, wanting to change society. For many researchers, all of this is day-to-day business. But what if you want to take your idea to market? This is a step that often does not come naturally to...
-
14 February 2023
Lift to the inclusive workplace
There is plenty of work, and yet people with a disability are still often sidelined. One plus one is two, or so you’d think: this is the perfect time to help this group of workers find a job. The intention is there, also within the University, but...
-
15 December 2022
Groningen contributes to major research initiative into energy-efficient information technology
The Dutch science funding agency NWO recently awarded a large research project into new concepts for energy-efficient information technology of no less than ten million euros